About RheumaGen
RheumaGen is a private company based in Denver, Colorado, incorporated in 2022 in Delaware. It has reported $7,906,587 raised in four offerings on Form D since October 2022.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 5, 2024 | Apr 17, 2024 | $700,000fully sold | 1 | $700K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Apr 4, 2024 | Apr 17, 2024 | $4,906,587of $15.0M target | 3 | $1.6M | EquityRule 506(b) | Form D ↗ |
| May 16, 2023 | May 26, 2023 | $300,000fully sold | 1 | $300K | Convertible Promissory NoteRule 506(b) | Form D ↗ |
| Oct 12, 2022 | Oct 18, 2022 | $2,000,000fully sold | 1 | $2.0M | Convertible Promissory NotesRule 506(b) | Form D ↗ |
| Total, four offerings | $7,906,587 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on RheumaGen's Form D filed Apr 17, 2024.
BG
Bruce Goodwin
Director
JJ
James Hart, Jr.
Executive officer
BM
Bobak Mozayeni
Executive officer
RH
Ryan Hart
Chief Legal Officer
TF
Thomas Fratacci
Director
BF
Brian Freed
Executive officer
RI
Richard Freed, III
Executive officer and director
Earlier filings also listed Gregory Andrews (director, last listed May 2023).